Canada Psoriasis Drugs Market Size & Outlook, 2025-2030
Related Markets
Canada psoriasis drugs market highlights
- The Canada psoriasis drugs market generated a revenue of USD 898.4 million in 2024 and is expected to reach USD 1,668.3 million by 2030.
- The Canada market is expected to grow at a CAGR of 11% from 2025 to 2030.
- In terms of segment, tumor necrosis factor inhibitors was the largest revenue generating class in 2024.
- InterleU.S.in Inhibitors is the most lucrative class segment registering the fastest growth during the forecast period.
Psoriasis drugs market data book summary
| Market revenue in 2024 | USD 898.4 million |
| Market revenue in 2030 | USD 1,668.3 million |
| Growth rate | 11% (CAGR from 2025 to 2030) |
| Largest segment | Tumor necrosis factor inhibitors |
| Fastest growing segment | InterleU.S.in Inhibitors |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tumor Necrosis Factor Inhibitors, InterleU.S.in Inhibitors, Vitamin-D Analogues, Corticosteriods |
Other key industry trends
- In terms of revenue, Canada accounted for 4.3% of the global psoriasis drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. psoriasis drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,668.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Psoriasis Drugs Market Scope
Psoriasis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | View profile | - | - | - |
| Celgene Corporation | View profile | - | - | - |
| Eli Lilly and Company | View profile | - | - | - |
| Johnson & Johnson Services, Inc. | View profile | - | - | - |
| Novartis AG | View profile | - | - | - |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
Canada psoriasis drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to psoriasis drugs market will help companies and investors design strategic landscapes.
Tumor necrosis factor inhibitors was the largest segment with a revenue share of 44.96% in 2024. Horizon Databook has segmented the Canada psoriasis drugs market based on tumor necrosis factor inhibitors, interleu.s.in inhibitors, vitamin-d analogues, corticosteriods covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Canada psoriasis drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada psoriasis drugs market databook
-
Our clientele includes a mix of psoriasis drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada psoriasis drugs market , including forecasts for subscribers. This country databook contains high-level insights into Canada psoriasis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Canada Class - Psoriasis Drugs Market size, 2024 - 2030 (US$M)
Canada Psoriasis Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
